Premium
Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long‐term cost‐effectiveness analysis
Author(s) -
Barnett Anthony H.,
Arnoldini Simon,
Hunt Barnaby,
Subramanian Gowri,
Hoxer Christina Stentoft
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13318
Subject(s) - liraglutide , sitagliptin , medicine , type 2 diabetes , glycated hemoglobin , diabetes mellitus , endocrinology
Aims The recent LIRA‐SWITCH trial showed that switching from sitagliptin 100 mg to liraglutide 1.8 mg led to statistically significant and clinically relevant improvements in glycated haemoglobin (HbA1C) and body mass index (BMI). Based on these findings, the aim of the present study was to assess the long‐term cost‐effectiveness of switching from sitagliptin to liraglutide in patients with type 2 diabetes in the UK. Materials and Methods The IQVIA CORE Diabetes Model Version 8.5+ was used to project costs and clinical outcomes over patients' lifetimes. Baseline cohort characteristics and treatment effects were derived from the LIRA‐SWITCH trial. Future costs and clinical benefits were discounted at 3.5% annually. Costs were accounted in pounds sterling (GBP) and expressed in 2016 values. One‐way and probabilistic sensitivity analyses were performed. Results Model projections showed improved quality‐adjusted life expectancy for patients with poorly controlled HbA1c upon switching from sitagliptin to liraglutide, compared with continuing sitagliptin treatment (9.18 vs 9.02 quality‐adjusted life years [QALYs]). Treatment switching was associated with increased overall costs (GBP 24737 vs GBP 22362). Higher pharmacy costs were partially offset by reduced diabetes‐related complication costs in patients who switched to liraglutide. Switching to liraglutide was associated with an incremental cost‐effectiveness ratio of GBP 15423 per QALY gained vs continuing with sitagliptin treatment. Conclusions Switching from sitagliptin 100 mg to liraglutide 1.8 mg in patients with poor glycaemic control was projected to improve clinical outcomes and is likely to be considered cost‐effective in the UK setting and, therefore, a good use of limited NHS resources.